-
Product Insights
NewEbolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2024
Empower your strategies with our Ebolavirus Infections (Ebola Hemorrhagic Fever) – Drugs In Development, 2024 report and make more profitable business decisions. Ebola is a rare but deadly viral infection that causes bleeding inside and outside the body. Signs and symptoms include fever, severe headache, joint and muscle aches, sore throat, nausea and vomiting, diarrhea, chest pain, and cough. Supportive therapy includes oxygen therapy, blood transfusions, intravenous fluids, and pain relievers. The Ebolavirus Infections (Ebola Hemorrhagic Fever) drugs in development market...
-
Product Insights
NewAcute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2024
Empower your strategies with our Acute Renal Failure (ARF) (Acute Kidney Injury) – Drugs In Development, 2024 report and make more profitable business decisions. Acute renal failure occurs when the kidneys suddenly become unable to filter waste products from blood. Symptoms include drowsiness, shortness of breath, fatigue, seizures or coma in severe cases, and chest pain. The predisposing factors include age, diabetes, high blood pressure, heart failure, and kidney diseases. Treatment includes antibiotics and diuretics. The Acute Renal Failure (ARF) (Acute...
-
Product Insights
NewInfluenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2024
Empower your strategies with our Influenza A Virus, H1N1 Subtype Infections – Drugs In Development, 2024 report and make more profitable business decisions. H1N1 infection, also known as swine flu, is a new kind of flu in humans caused by a contagious influenza virus strain. H1N1 flu infects the nose, throat, and lungs. It is spread by droplets distributed by coughing or sneezing. Signs and symptoms include cough, fever, sore throat, stuffy or runny nose, body aches, headache, and fatigue. Treatment...
-
Product Insights
NewThrombosis – Drugs In Development, 2024
Empower your strategies with our Thrombosis – Drugs In Development, 2024 report and make more profitable business decisions. Thrombosis is the formation of a blood clot, known as a thrombus, within a blood vessel. This clot can obstruct the normal blood flow, potentially leading to various health complications. Thrombosis can occur in both veins and arteries. Common types include Deep Vein Thrombosis (DVT), where clots form in deep veins, often in the legs, and Pulmonary Embolism (PE), which occurs when a...
-
Product Insights
NewRespiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024
Empower your strategies with our Respiratory Syncytial Virus (RSV) Infections – Drugs In Development, 2024 report and make more profitable business decisions. Respiratory syncytial virus (RSV) infection is a respiratory disease. RSV commonly causes bronchiolitis (inflammation of the small airways in the lung) and pneumonia in children less than one year of age. The symptoms of RSV infection include cough, stuffy or runny nose, mild sore throat, earache, and fever. Treatment includes proper medication and hygiene practice. The Respiratory Syncytial Virus...
-
Product Insights
NewInfluenzavirus A Infections – Drugs In Development, 2024
Empower your strategies with our Influenzavirus A Infections – Drugs In Development, 2024 report and make more profitable business decisions. Influenza A virus infections are caused by a type of influenza virus with a high capacity for genetic variation. It is more serious than the common cold and can cause major outbreaks and severe disease. It spreads through droplets from the nose or throat of an infected person, usually through coughing and sneezing. The proteins on the surface of the influenza...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ondansetron Hydrochloride CR in Gastroenteritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ondansetron Hydrochloride CR in Gastroenteritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ondansetron Hydrochloride CR in Gastroenteritis Drug Details: Ondansetron hydrochloride (RHB-102, Bekinda)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ondansetron Hydrochloride CR in Gastritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ondansetron Hydrochloride CR in Gastritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ondansetron Hydrochloride CR in Gastritis Drug Details: Ondansetron hydrochloride (RHB-102, Bekinda)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Opaganib in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Opaganib in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Opaganib in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Opaganib (ABC-294640)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Talimogene Laherparepvec in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Talimogene Laherparepvec in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Talimogene Laherparepvec in Basal Cell Carcinoma...